Ignite Planners LLC boosted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Get Rating) by 281.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 12,888 shares of the medical device company’s stock after acquiring an additional 9,506 shares during the quarter. DexCom accounts for about 0.9% of Ignite Planners LLC’s investment portfolio, making the stock its 25th largest holding. Ignite Planners LLC’s holdings in DexCom were worth $1,056,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Jennison Associates LLC increased its position in DexCom by 83.4% in the 1st quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock worth $1,330,305,000 after buying an additional 1,182,632 shares during the period. Sands Capital Management LLC grew its holdings in shares of DexCom by 33.9% during the 1st quarter. Sands Capital Management LLC now owns 4,189,245 shares of the medical device company’s stock worth $2,143,218,000 after purchasing an additional 1,060,655 shares in the last quarter. Clearbridge Investments LLC grew its holdings in shares of DexCom by 304.3% during the 1st quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after purchasing an additional 992,049 shares in the last quarter. Capital Research Global Investors grew its holdings in shares of DexCom by 55.2% during the 4th quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock worth $1,275,020,000 after purchasing an additional 844,916 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of DexCom during the 4th quarter worth approximately $410,670,000. 92.34% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on DXCM shares. Sanford C. Bernstein started coverage on DexCom in a research report on Friday, July 15th. They set an “outperform” rating and a $105.00 target price for the company. Cowen reiterated a “buy” rating and set a $85.00 target price on shares of DexCom in a research note on Friday, July 29th. Robert W. Baird lowered their price objective on DexCom from $115.00 to $97.00 in a research note on Friday, July 29th. Citigroup reduced their target price on DexCom from $105.00 to $100.00 in a report on Friday, July 29th. Finally, Piper Sandler cut their price objective on DexCom from $120.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, July 29th. Two analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $115.23.
Insider Buying and Selling
DexCom Trading Down 1.2 %
DexCom stock traded down $0.95 during midday trading on Friday, hitting $80.01. 42,506 shares of the stock were exchanged, compared to its average volume of 2,245,621. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $164.86. The stock has a market capitalization of $31.41 billion, a price-to-earnings ratio of 165.82, a PEG ratio of 3.41 and a beta of 1.03. The stock’s 50-day simple moving average is $86.18 and its 200 day simple moving average is $91.47. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.87.
DexCom (NASDAQ:DXCM – Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). DexCom had a net margin of 7.47% and a return on equity of 11.79%. The company had revenue of $696.20 million for the quarter, compared to analyst estimates of $709.33 million. During the same quarter in the prior year, the business earned $0.19 earnings per share. DexCom’s revenue was up 17.0% on a year-over-year basis. On average, equities analysts anticipate that DexCom, Inc. will post 0.79 EPS for the current year.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- Why Does Tesla Stock Remain Resilient?
- Is Costco’s Post-Earnings Price Weakness A Good Time To Buy?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.